Clinical Trial Search

Primary: Time From First Vaccination to the Detection of the First New Malaria Infection Through to the Month 20 Study Visit — 43.1; 43.9; 39; 39 Weeks

Primary: Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation — -16.143…

Primary: Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh) — 4.6; 4.2; 11.7; 9.9 mL/100 mL tissue/min

Primary: Cmax: Maximum Observed Plasma Concentration for Brigatinib — 366.6; 397.6 nanogram per millliliter (ng/mL)

Primary: Number of Participants With Treatment- Emergent Adverse Events (TEAEs) — 36 Participants

Primary: Joint Contact Stress Time Exposure (Model Estimated) — 4.44; 3.97; 4.08; 4.25 MPa-s/gait cycle

Primary: Percentage of Heavy Drinking Days, PHDD — 24.4; 21.4; 21.3 percentage of heavy drinking days — p=0.688

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Discontinuation Due to TEAEs and Death — 5; 1; 1; 0 Participants

Primary: Number of Participants With Unfavorable Wound Healing Outcomes at 4 Weeks — 8; 7 Participants

Primary: Anxiety Potentiated Startle — 4.600026484; 3.411297242; 3.122643391; 4.848463905 T-scores

Primary: Residual Volume at 1st Flow-stop (Catheterisation Performed by HCP) — 15.3; 23.7 mL

Primary: Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS)) — -11.5; -15.0; -17.8; -6.8 score on a scale

Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851

Primary: State-Trait Anxiety Inventory — 32.8; 32.5 Score on a scale — p=.694

Primary: Determine the RPII Dose of NC-6004 in Combination With Gemcitabine — 0; 0; 0; 0 Participants